ArticleHealth science reports2025
Impact of Angiotensin-Converting Enzyme Inhibitor on Coronary Artery Calcification Evaluated by Intravascular Ultrasound: A Retrospective Cohort Study.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Coronary artery calcification (CAC) is a predictor of poor prognosis after percutaneous coronary intervention (PCI), and its treatment depends on calcification severity assessed by intravascular imaging such as intravascular ultrasound (IVUS). We aimed to investigate the factors associated with CAC severity and clinical outcomes, with a particular focus on the potential impact of angiotensin-converting enzyme inhibitor (ACEI) use. Methods: We retrospectively analyzed 630 patients with stable coronary artery disease who underwent IVUS-guided PCI between January 2018 and March 2023. Calcification severity was assessed using IVUS, and patients were grouped into moderate/severe and none/mild calcification. Outcomes included all-cause death and major adverse cardiovascular and cerebrovascular events (MACCEs). Results: Patients with moderate/severe calcification had a significantly lower survival rate and a higher incidence of MACCEs ( Conclusion: IVUS-assessed moderate/severe calcification is a strong predictor of all-cause death and MACCE in patients with CAD undergoing PCI. ACEI use was associated with less severe calcification and a lower incidence of MACCE in these patients. Evaluation of calcification may help identify high-risk patients and guide anti-calcification treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.